This paper is only available as a PDF. To read, Please Download here.
Background: In clinical studies, nebivolol at doses of 2.5 to 40 mg once daily was associated with significant decreases in systolic blood pressure (SBP) and diastolic BP (DBP) in patients with hypertension and was well tolerated.
Objectives: This post hoc analysis of pooled data from 2 previously published registration studies was conducted to further evaluate the antihypertensive efficacy and tolerability of nebivolol in patients with mild to moderate (stage 1–2) hypertension.
Methods: The 2 trials were similarly designed multicenter, 12-week, randomized, double-blind, placebocontrolled, parallel-group, dose-ranging studies in patients 18 years of age and older with stage 1 or 2 hypertension (SBP 140–159 mm Hg and/or DBP 90–99 mm Hg [stage 1] or SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg [stage 2]). The primary efficacy end point of the 2 studies was the change from baseline in mean trough SiDBP at week 12. A secondary end point was the change from baseline to week 12 in mean trough sitting SBP (SiSBP). The present analysis included only patients who received nebivolol 5, 10, or 20 mg (the doses were common to both studies) or placebo, including analyses stratified by baseline SBP, although DBP represented a criterion for entry into the studies. Baseline SBP stratification levels were 140 to 149 mm Hg, 150 to 159 mm Hg, 160 to 169 mm Hg, and 170 to 179 mm Hg. For the tolerability analysis, the prevalences of treatment-emergent adverse events (AEs) were compared between the 3 nebivolol dose groups and the placebo group.
Results: Of the 1716 randomized patients who received study medication in the 2 trials, data from 1385 patients were included in this pooled analysis (759 men, 626 women; median age, ~54 years; 13.6% black). Mean (SD) baseline SiSBP and SiDBP values were 151.9 to 152.7 and 99.2 to 99.5 mm Hg, respectively. Reductions from baseline in trough SiSBP were −10.8 (13.5), −10.7 (14.7), and −12.4 (15.5) mm Hg with nebivolol 5, 10, and 20 mg, respectively, compared with −4.5 (13.4) mm Hg with placebo (all, P < 0.001). Reductions from baseline in trough SiDBP (the primary end point) were −9.8 (7.9), −10.5 (8.2), and −11.1 (8.6) mm Hg with nebivolol 5, 10, and 20 mg, respectively, compared with −5.1 (8.1) mm Hg with placebo (all, P < 0.001). In a subgroup of 1227 patients stratified by baseline SBP, the reductions in SBP and DBP were significantly greater (P < 0.03 and P < 0.001, respectively) with nebivolol at each dose compared with placebo in those with baseline SBP of 140 to 149 mm Hg and 150 to 159 mm Hg (the lowest 2 baseline strata); in the highest 2 baseline strata (SBP 160–169 and 170–179 mm Hg), the reductions in SBP with nebivolol 5 mg and nebivolol 20 mg in the 160 to 169-mm Hg baseline SBP stratum and in DBP with nebivolol 20 mg in the 170 to 179-mm Hg baseline stratum were significantly greater (P < 0.03) compared with placebo. The most common AE in the nebivolol 5−, 10−, and 20-mg groups and the placebo group was headache (36/409 [8.8%], 25/410 [6.1%], 27/410 [6.6%], and 10/156 [6.4], respectively), fol-lowed by fatigue (9/409 [2.2%], 10/410 [2.4%], 25/410 [6.1%], and 3/156 [1.9%]) and dizziness (6/409 [1.5%], 9/410 [2.2%], 15/410 [3.7%], and 4/156 [2.6%]).
Conclusion: The present analysis of pooled data from 2 previously published registration studies found that nebivolol was associated with significant reductions in BP compared with placebo in these patients with stage 1 or 2 hypertension, with a tolerability similar to that of placebo.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Therapeutics
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome.Hypertension. 2005; 45: 907-913
- The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003;290:197].JAMA. 2003; 289: 2560-2572
- Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States.Arch Intern Med. 2000; 160: 825-831
- Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2009;119:e182].Circulation. 2009; 119: e21-e181
- Antihypertensive effect of irbesartan and predictors of response in obesityassociated hypertension: A prospective, open-label study.Clin Drug Investig. 2005; 25: 765-776
- Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled.Am J Hypertens. 2004; 17: 904-910
- Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: The Global Cardiometabolic Risk Profile in Patients with hypertension disease survey.J Hypertens. 2008; 26: 2064-2070
- Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004.Hypertension. 2008; 52: 818-827
- Hypertension in adults across the age spectrum: Current outcomes and control in the community.JAMA. 2005; 294: 466-472
- Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy.JAMA. 1998; 280: 1168-1172
- Pharmacology of nebivolol.Pharmacol Res. 1998; 38: 419-431
- Nebivolol in the management of essential hypertension: A review.Drugs. 1999; 57: 633-651
- Nebivolol: More than a highly selective beta blocker.Recent Pat Cardiovasc Drug Discov. 2007; 2: 152-155
- A randomized, doubleblind, placebo-controlled parallelgroup study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension [published correction appears in J Clin Hypertens (Greenwich). 2007;806].J Clin Hypertens (Greenwich). 2007; 9: 667-676
Greathouse M. Nebivolol efficacy and safety in patients with Stage I-II hypertension. Clin Cardiol. In press.
- The efficacy and tolerability of nebivolol in hypertensive African American patients.J Clin Hypertens (Greenwich). 2007; 9: 866-875
- Chapman & Hall, London, UK1991 Practical Statistics for Medical Research.
- The burden of adult hypertension in the United States 1999 to 2000: A rising tide.Hypertension. 2004; 44: 398-404
- The disease burden associated with overweight and obesity.JAMA. 1999; 282: 1523-1529
- Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.JAMA. 2003; 290: 199-206
- Differential control of systolic and diastolic blood pressure: Factors associated with lack of blood pressure control in the community.Hypertension. 2000; 36: 594-599
- Predominance of isolated systolic hypertension among middleaged and elderly US hypertensives: Analysis based on National Health and Nutrition Examination Survey (NHANES) III.Hypertension. 2001; 37: 869-874
- 2007 Guidelines for the management of arterial hypertension.Eur Heart J. 2007; 28: 1462-1536
- Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.BMJ. 1998; 317: 703-713
- Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial.J Hypertens. 2004; 22: 847-857
- Hypertension control in the elderly.J Clin Hypertens (Greenwich). 2008; 10: 33-39
- Clinical practice and recent recommendations in hypertension management-reporting a gap in a global survey of 1259 primary care physicians in 17 countries.Curr Med Res Opin. 2007; 23: 783-791
- Safety and tolerability of nebivolol: a pooled analysis comparing typical β-blocker-associated adverse events with those of placebo.J Clin Hypertens (Greenwich). 2008; 10: A120
- Glucose control in hypertensive patients treated with the vasodilating, selective beta-blocker, nebivolol.South Med J. 2008; 101: 863
- Long term effects of the novel beta-blocker, nebivolol, on blood glucose in hypertensive patients.South Med J. 2008; 101: 863
- Nebivolol in obese and nonobese hypertensive patients.J Clin Hypertens (Greenwich). 2009; 11: 309-315
Accepted: August 23, 2009
© 2009 Excerpta Medica Inc. All rights reserved. Published by Elsevier Inc.